ad6548b723
- Source: inbox/queue/2026-04-24-arpa-h-evident-139m-behavioral-health-psychedelics.md - Domain: health - Claims: 0, Entities: 4 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
1.6 KiB
Diamond Therapeutics
Location: Toronto, Canada
Focus: Psilocybin-assisted therapy for anxiety disorders
Stage: Phase 2a clinical trials
Clinical Programs
Generalized Anxiety Disorder (GAD):
- Phase 2a psilocybin trial data being contributed to ARPA-H EVIDENT initiative
- GAD represents largest single anxiety disorder population (~40M US sufferers)
- Larger addressable market than treatment-resistant depression (TRD) or PTSD
Strategic Position
Diamond Therapeutics is notable as a Canadian company selected for US government-funded research infrastructure (ARPA-H EVIDENT), demonstrating international data integration into US regulatory pathways. The GAD indication differentiates from most psychedelic research focused on depression or PTSD.
Timeline
- 2026-04-24 — Selected as ARPA-H EVIDENT research team, contributing Phase 2a psilocybin GAD trial data
Analysis
The GAD indication is strategically significant: if psilocybin demonstrates efficacy for generalized anxiety disorder, the addressable population exceeds TRD and PTSD combined. GAD affects ~6.8M US adults annually (3.1% of population), with lifetime prevalence near 9%. Current first-line treatments (SSRIs, SNRIs, benzodiazepines) have limited efficacy and significant side effect profiles, creating unmet medical need.
Diamond's inclusion in ARPA-H EVIDENT despite being a non-US company indicates that psychedelic research infrastructure is genuinely international, with US regulatory agencies willing to incorporate foreign clinical data into domestic approval pathways.